PHARMING GROUP NV

Pharming Group N.V. announced a public cash offer to acquire all shares of Abliva AB for SEK 0.45 per share, valued at US$66.1 million. Abliva's Board recommended shareholders accept the offer, with the acceptance period expected from January 16 to February 7, 2025. Abliva's KL1333 is in a pivotal clinical trial for mitochondrial diseases.

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of scraping tools. Account typically reactivates within 24 hours; contact support if still disabled.

MHRA approves Pharming Group’s Joenja (leniolisib) for activated phosphoinositide 3-kinase delta syndrome (APDS), the first drug for this rare immune disease in the UK. Indicated for adults and adolescents aged 12+ weighing at least 45kg, Joenja reduces lymph node size and improves B cell counts. Approval via the International Recognition Procedure (IRP) was supported by a 12-week study.